Neurological Surgery 脳神経外科46巻12号

2018年12月発行

連載 教訓的症例に学ぶシリーズ

頭蓋内出血を併発したダビガトラン（プラザキサ^®）内服例に対するイダルシズマブ（プリズバインド^®）の効果

著者： 刈部博¹ 赤松洋祐¹ 成澤あゆみ¹ 林俊哲¹ 亀山元信¹

所属機関： ¹仙台市立病院脳神経外科

ページ範囲：P.1117 - P.1120

Ⅰ．経験症例
　〈症例1〉　90歳　男性
　現病歴　徐脈性心房細動および脳梗塞の既往があり，ダビガトラン（プラザキサ^®）220mg/dayを内服中であった．5週間前に転倒し，数日前から左不全片麻痺が出現して，近医より当科紹介となった．

参考文献

1) Ashburner JM, Singer DE, Lubitz SA, Borowsky LH, Atlas SJ：Changes in use of anticoagulation in patients with atrial fibrillation within a primary care network associated with the introduction of direct oral anticoagulants. Am J Cardiol 120：786-791, 2017

-VASc score（beyond sex）receive oral anticoagulation?. J Am Coll Cardiol 65：635-642, 2015

3) Cuker A, Siegal DM, Crowther MA, Garcia DA：Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64：1128-1139, 2014

4) Gendron N, Feral-Pierssens AL, Jurcisin I, de Raucourt E, Bouton V, Fischer AM, Lorenceau-Savale C, Lillo-Le Louët A, Smadja DM：Real-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding. Clin Case Rep 5：346-350, 2017

5) Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J：Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers：a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 386（9994）：680-690, 2015

6) Grottke O, Aisenberg J, Bernstein R, Goldstein P, Huisman MV, Jamieson DG, Levy JH, Pollack CV Jr, Spyropoulos AC, Steiner T, Del Zoppo GJ, Eikelboom J：Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Crit Care 20：115, 2016

7) Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, Ezekowitz MD, Yusuf S：Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran：the RE-LY trial. Stroke 43：1511-1517, 2012

8) Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P；ESC Scientific Document Group：2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37：2893-2962, 2016

9) Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI；Subcommittee on Control of Anticoagulation：When and how to use antidotes for the reversal of direct oral anticoagulants：guidance from the SSC of the ISTH. J Thromb Haemost 14：623-627, 2016

10) Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI：Idarucizumab for dabigatran reversal. N Engl J Med 373：511-520, 2015

11) Raval AN, Cigarroa JE, Chung MK, Diaz-Sandoval LJ, Diercks D, Piccini JP, Jung HS, Washam JB, Welch BG, Zazulia AR, Collins SP；American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology；Council on Cardiovascular Disease in the Young；and Council on Quality of Care and Outcomes Research：Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting：a scientific statement from the American Heart Association. Circulation 135：e604-e633, 2017

12) Tsai LK, Lin HJ, Chua SK, Liao PC, Yang YP, Chou PC, Lee CW, Lin MJ, Chen HM, Yeh JT, Li YH：Real-world experience with idarucizumab to reverse anticoagulant effect in dabigatran-treated patients：report of 11 cases from Taiwan. J Stroke Cerebrovasc Dis 27：e27-e33, 2018

13) Vosko MR, Bocksrucker C, Drwiła R, Dulíček P, Hauer T, Mutzenbach J, Schlimp CJ, Špinler D, Wolf T, Zugwitz D：Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients：a series of 11 cases. J Thromb Thrombolysis 43：306-317, 2017